Dr. Evangelos Terpos on the Results of the DARIA Study

Background of the study:

Second-line treatment of patients (pts) with multiple myeloma (MM), who are refractory to, or have relapsed after frontline lenalidomide-based therapy is challenging. Daratumumab (DARA), an anti-CD38 monoclonal antibody, has shown significant clinical activity and an acceptable safety profile in pts with relapsed/refractory multiple myeloma (RRMM) as monotherapy or in combination with other agents. Ixazomib, the first oral proteasome inhibitor, has also been shown to be efficacious and with a positive safety profile in newly diagnosed multiple myeloma patients.

In this video:

Dr. Evangelos Terpos (National and Kapodistrian University of Athens, Athens, Greece) discusses the results of the DARIA study which evaluated the effectiveness of DARA in combination with ixazomib and dexamethasone as second-line therapy in patients with RRMM who have previously been treated with a lenalidomide-based regimen.

Conclusions:

Second-line treatment with daratumumab, ixazobmib, and dexamethaonse (DId) in patients with RRMM who were previously treated with a lenalidomide-based regimen resulted in rapid (median time to partial response or better was less than a month) and deep responses (about a third of patients exhibited Very Good Partial Response or better). The safety profile of DId was very good, and the majority of patients (60%) did not experience grade 3/4 adverse events, whereas 25% of them experienced a serious adverse event.